Pediatric patients with transfusion-dependent thalassemia or SCD face lifelong iron chelation. Their clinical care differs from adults in important ways.
1. Initiation Timing #
Chelation is typically initiated after ~20 transfusions or when ferritin persistently exceeds 1000 ng/mL - often from around age 2 years for thalassemia major. Earlier starts require the finer titration strengths (100 mg, 125 mg).
2. Weight-Based Dosing #
Deferasirox dispersible tablets are dosed on a mg/kg basis. The 100 mg and 125 mg unit sizes allow accurate stepping from 5 mg/kg/day to higher doses as needed. Regular weight measurement updates the dose.
3. Tubulopathy Risk #
Pediatric patients have a higher risk of Fanconi-like tubulopathy - proximal tubular dysfunction with glycosuria, aminoaciduria and phosphaturia. Regular urinalysis and electrolyte monitoring are essential. Discontinue if tubulopathy develops.
4. Growth and Development #
Long-term chelation programmes monitor height velocity, pubertal staging and endocrine function. Iron-related endocrine complications (hypogonadism, hypothyroidism, diabetes) become more relevant in adolescence and young adulthood if iron burden is not controlled.
5. Audiology and Ophthalmology #
Annual hearing and lens screening are recommended. Early detection of deferasirox-related or iron-related ocular/auditory changes supports timely dose adjustments.
6. Adherence Support #
- Age-appropriate education for patient and caregiver
- Standardised dispersible-tablet preparation routine
- Empty-stomach administration at the same time every day
- Written adherence plans and pharmacy refill reminders
- School liaison where appropriate
7. Transition to Adult Care #
Structured transition from pediatric to adult hematology services preserves continuity of chelation and monitoring - a known vulnerability period for adherence.
See Special Populations for detailed pediatric guidance.